Document is current
Any future updates will be listed below
-
Authors
Osman, Allen M.
Madore, Kevin P.
Jaffe, Paul I.
Offidani, Emanuela
Childress, Ann C.
Newcorn, Jeffrey H.
Schafer, Robert J.
-
Funding
Funding for this research was provided by:
Lumos Labs, Inc.
- License Information
-
More Information
Article History
Received: 25 April 2024
Accepted: 1 August 2025
First Online: 22 August 2025
Competing interests
: This study was supported entirely by Lumos Labs, Inc. At the time of the study, AMO, EO, KPM, PIJ, and RJS were paid employees of the company. All hold stock in the company. Over the last three years, ACC received research support, served on an advisory board, was as a consultant or speaker, or received writing support from the following: Aardvark, Acadia, Adlon, Akili, Allergan, Attentive, Axial, Cingulate, Corium, Emalex, Ironshore, Kempharm, Lumos Labs, Neurocentria, Noven, Otsuka, Purdue, Receptor Life Sciences, Sunovion, Supernus, Takeda, Tris and Tulex. Over the last three years, JHN was a consultant/advisory board member for Adlon Therapeutics, Cingulate Therapeutics, Corium, Hippo T&C, Ironshore, Lumos Labs, Medice, MindTension, Myriad, NLS, OnDosis, Otsuka, Rhodes, Shire/Takeda, Signant Health and Supernus. He also received research support from Adlon, Otsuka, Shire, Supernus; honoraria for disease state lectures from Otsuka and Shire; and served as a consultant for the US National Football League.
